NEW YORK – Fluidigm said on Tuesday that it has signed a distribution deal with De Novo Software to offer that firm's data-analysis tools alongside Fluidigm's mass cytometer platforms.
Under the agreement, new purchases of Fluidigm's Helios mass cytometer and Hyperion imaging system will include a one-year license for De Novo's FCS Express 7 Flow software for suspension data analysis.
In general, the FCS Express platform enables rapid generation of analysis reports, manual or semi-automated high-dimensional analysis tools, and custom report templates. FCS Express Flow, De Novo's flagship product, enables the design of custom analysis templates, with streamlined outputs into Microsoft Office applications, while maintaining high-resolution graphics and reports.
"There are more than 1,000 significant publications based on mass cytometry, a technology that provides researchers with extraordinary capabilities in interrogating the tissue microenvironment to explore important questions in developmental biology, disease progression, and response to therapy," Fluidigm President and CEO Chris Linthwaite said in a statement. "In order to fully realize the value of these rich datasets, novel analysis methods are essential. We are pleased to offer our customers access to the considerable capabilities provided by De Novo's software solutions."